Alzheimer's drug adoption in US slowed by doctors' skepticism
By Julie Steenhuysen CHICAGO (Reuters) - Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some …